Open an account

Kadant

KAI · NYSE

$264.81+$1.04 (+0.39%)TodayMarket closed ·
Prev close $263.77

About KAI

Kadant Inc. operates as a global supplier of critical components and engineered systems used in process industries worldwide. The company is headquartered in Westford, Massachusetts and currently employs 3,900 full-time employees. The Company’s segments include Flow Control, Industrial Processing, and Material Handling. Its Flow Control segment provides custom-engineered products, systems, and technologies that control the flow of fluids used in industrial and commercial applications to keep critical processes running efficiently in the packaging, tissue, food, metals, energy, and other industrial sectors. Its Industrial Processing segment provides equipment, machinery, and technologies used to recycle paper and paperboard and process timber for use in the packaging, tissue, wood products and alternative fuel industries, among others. Its Material Handling segment provides products and engineered systems used to handle bulk and discrete materials for secondary processing or transport in the aggregates, mining, food, and waste management industries, among others.

Employees
3,900
Headquarters
Westford, Massachusetts
Listed
Nov 3, 1992
Sector
Industrials
Industry
Machinery
Website
kadant.com

KAI key statistics

Market cap
3.13B
Price-earnings ratio
28.36
Dividend yield
0.51%
Average volume
129.51K
Volume
107.12K
Open price
$262.03
High today
$268.43
Low today
$262.01
52 Week high
$354.07
52 Week low
$244.87

Kadant (KAI) at a glance

Kadant (KAI) last traded at $264.81, with a market cap of 3.13B, a price-to-earnings ratio of 28.36 and a dividend yield of 0.51%.

Today the stock has traded between $262.01 and $268.43. The current price is 1.1% above the day's low and 1.3% below its high.

Volume so far is 107.12K shares, in line with the average of 129.51K shares a day.

Over the past year Kadant has ranged from $244.87 to $354.07, and now sits 18% of the way up that range.

Kadant met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $3.42 per share against an estimate of $2.97.

The average analyst price target is $364.65, 37.7% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 3 analystsAvg $364.65
Low
$338.35
Now
$264.81
High
$399.00

KAI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 13.6% on average.

  1. Q3 FY24: reported $2.84 per share against an estimate of $2.45
  2. Q4 FY24: reported $2.25 per share against an estimate of $2.10
  3. Q1 FY25: reported $2.10 per share against an estimate of $1.99
  4. Q2 FY25: reported $2.31 per share against an estimate of $2.10
  5. Q3 FY25: reported $2.59 per share against an estimate of $2.20
  6. Q4 FY25: reported $2.27 per share against an estimate of $2.21
  7. Q1 FY26: reported $2.84 per share against an estimate of $2.11
  8. Q2 FY26: reported $3.42 per share against an estimate of $2.97

KAI news

  • Full Transcript: Kadant Q1 2026 Earnings Call

  • Earnings Outlook For Kadant

  • A Look at Kadant's Upcoming Earnings Report

  • 12 Industrials Stocks Moving In Friday's Pre-Market Session

  • Press releaseBusiness Wire

    Modivcare Announces Changes to Board of Directors

  • Press releasePRNewswire

    Kadant Set to Join S&P SmallCap 600

Similar companies

Companies in the same industry as Kadant

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.